Work

Silymarin-alpha lipoic acid and metabolic dysfunction-associated steatotic liver disease: Insights and methodological considerations

Year: 2025

Type: article

Abstract: and alpha-lipoic acid (SM-ALA), combined with a Mediterranean diet, in patients with metabolic dysfunction-associated steatotic liver disease. While some metabolic benefits were observed, limitations such as the absence of an SM-ALA-only group, the lack of histological data, and a small sample size reduce the validity of the findings. Future research should follow clinical trial standards for pharmacological studies, including phase 1/2 testing, validated outcomes, and transparency.

Source: World Journal of Hepatology

DOI: 10.4254/wjh.v17.i9.110162

Authors: Froylan David Martínez-Sánchez, Sophia Eugenia Martínez-Vázquez, Ricardo Gutiérrez-Monterrubio, Sergio Muñoz-Martínez, Ignacio Garcia-Juarez

Institutions: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Centro Médico ABC

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond